

a PROMISE in action



CONTENTS

LETTER FROM THE BOARD CHAIR	1
TEN YEAR STATEMENT OF ACTIVITIES	4
RESEARCH	5
EDUCATION	8
SCREENING	10
TREATMENT	12
FINANCIAL STATEMENTS	14
SUPPORT	17
RESEARCH GRANTS	20
BOARD OF DIRECTORS	26
OUR FOUNDER	28
STAFF LEADERSHIP	28

a PROMISE in action

From a promise between sisters to an international movement 75,000 volunteers strong – in nearly 25 years, the Komen Foundation has changed the way the world confronts breast cancer. We no longer whisper about the disease behind closed doors, we race by the millions in search of a cure.

Nancy Brinker promised her sister she would do everything she could to bring an end to breast cancer shortly before Suzy died from the disease at the age of 36. The Komen Foundation is the realization of a sister's dedication – it is a promise in action. From advances in screening technology, to treatment accessibility – yearly, even daily, long strides are being made toward achieving our mission to eradicate breast cancer as a life-threatening disease by advancing research, education, screening and treatment.

RESEARCH

Suzy Komen was convinced her sister could impact the fight against breast cancer. “You can find a way to speed up research. I know you can,” she told Nancy. And she was right. Today, our Foundation is one of the world's largest private funding sources for breast cancer research. In fiscal year 2005, 202 research grants were funded totaling more than \$45 million. We continued to focus our research grant dollars where we can make the greatest difference. We funded research that identifies the causes of breast cancer so we can find ways to prevent it, how to reduce risk, how to detect cancer earlier and more progressive methods of diagnosis and treatment. Recognizing that every year in the U.S., fewer women are dying from the disease, we also supported studies aimed at improving the quality of life for survivors. Specific examples of the research we funded appear on pages 5-7 and 20-25 of this report. In addition to funding research grants, the Foundation continued to support a meritorious award program that includes the Komen Foundation's Brinker Award for Scientific Distinction, the Komen Foundation Scholarship Program, Komen Interdisciplinary Fellowships and the Komen Professor of Survivorship Awards.

EDUCATION

From the beginning, the Foundation has had a strong commitment to education and over the years we have continued to reach out to new populations and new audiences. This year, 28 percent of the Foundation's spending income supported education efforts. Nationally, we launched On the Way to the Cure™ – The Komen College Tour as part of our Young Women's Initiative. The interactive educational tour is aimed at encouraging younger women to make a commitment to life-long breast health practices. We also previewed our new Komen Co-Survivor Program at the Komen National Race for the Cure® and rolled out *KomenLink*, our monthly e-Newsletter. Through national programs and Affiliate grants, we now provide or fund breast cancer education in more than 20 languages including Albanian, Arabic, Cambodian, Korean, Polish, Russian, Somali, Spanish and Thai.

In communities across the United States, our Domestic Affiliate Network sponsored a broad range of dynamic and innovative programs designed to address their own community's unique needs. This year, the Komen Philadelphia Affiliate hosted Sisters for the Cure™, a breast health education event targeting African Americans. In Chicago, a Komen Foundation Affiliate grant helped pay for the production of a breast health video for the deaf in American Sign Language. Two of our Colorado Affiliates funded one-on-one outreach for education and screening for homeless women, and in Florida, Komen dollars from two Affiliates addressed the challenges of providing breast health services for migrant farm workers.

Halfway across the country, our Des Moines Affiliate sponsored a program that educated physicians on how to document lymphedema symptoms so insurance companies would cover treatment costs. On the west coast, the Komen Oregon/SW Washington Affiliate paid for the training of eight Native American women to act as breast health advocates in their communities – each charged with finding 50 women who had not had mammograms and signing them up for free screening.

SCREENING

The earlier breast cancer is detected, the greater the chance for survival. Removing barriers to screening practices and working to improve imaging technologies and quality is key to our mission. Among the successes achieved in this area is the Mammography Quality Standards Reauthorization Act of 2004, a bill strongly supported by the Komen Foundation that was unanimously passed by both houses of Congress. This act extends through 2007 the safety and quality assurance protections we worked to guarantee in 1992, and includes additional provisions regarding facility certification.

This year, almost every Komen Affiliate funded screening programs for the medically underserved in their service areas. Grants also helped provide transportation, child care and other services aimed at making screening more accessible. In Atlanta, we funded a grant to help pay for genetic testing of high-risk indigent women. The Indianapolis Affiliate funded interpretation services to enable non-English speaking women to communicate with health care professionals during screenings. In Phoenix and throughout the country, Komen grants funded screening programs offered in conjunction with other medical and non-medical services with the goal of expanding diagnostic access to wider populations.

TREATMENT

Through Komen Affiliates, the Foundation supported numerous programs that provided financial assistance for treatment such as mastectomies, lumpectomies, chemotherapy and radiation, but our support for the patient didn't end there. From post-operative exercise programs, to helping pay for the delivery of fresh, nutritional meals to patients – many of the grants that Komen Affiliates funded in this area addressed the patient's quality of life following surgery, during radiation therapy or as he or she underwent chemotherapy.

The Houston Affiliate funded a program offering professional emotional therapy for breast cancer patients and their families, and in New Jersey, patients had access to free or low-cost prosthetic bras and wigs through an Affiliate grant. In Elmira, NY, the Affiliate funded radiation care kits that included products to help prevent skin irritation caused by treatment.

Research, education, screening and treatment – these are the areas in which we can measure our success. These are the areas where Nancy's promise to Suzy is put into action. Whether it is the Komen volunteer handing out water at a Komen Race for the Cure® event, helping raise money for research and community programs, or the thousands of activists advocating for more comprehensive Medicare coverage for breast cancer patients – Komen volunteers put our promise in action every day in so many different ways.

In the next year we will focus more acutely on the areas of causation and treatment disparities. Research grants will be even more specifically directed to study the causes of breast cancer and on trying to identify the needs, trends and barriers to breast health care in different populations. We made progress in 2004-2005, but there were still women diagnosed too late because of inadequate breast health information or access to care. Important research went unfunded. Our work is a promise in action – a promise we share and a promise we can't let go of until we eradicate breast cancer as a life-threatening disease. Thank you for your continued support.




LaSalle D. Leffall, Jr., M.D.
Chair of the Komen Foundation Board of Directors



TEN YEAR STATEMENT OF ACTIVITIES


*Without Value of Contributed Goods and Services

**Excluding 2001 Stub Period



TOTAL FOUNDATION SPENDING 2004-2005

*Without Value of Contributed Goods and Services



In fiscal year 1995, the Komen Foundation invested \$10.1 million in the fight against breast cancer. Ten years later, in fiscal year 2005, the Foundation invested \$135.8 million. This incredible growth has allowed us to further our mission by advancing research, education, screening and treatment worldwide. And while our growth over the past 10 years has been significant, we are committed to ensuring this momentum continues, pushing us forward, searching for answers, putting our promise in action.

The mission of the Komen Foundation is to eradicate breast cancer as a life-threatening disease by advancing **RESEARCH**, education, screening and treatment.

HOW DO WE DECIDE WHAT TO FUND?

In 2004-2005, the Komen Foundation received more than 800 research grant applications from scientists and clinicians around the globe. In the case of basic, clinical and translational research grants, applications are reviewed through a double blind, or anonymous, peer-review process – meaning the reviewers do not know the name of the applicant nor his or her institution. In addition, the applicants do not know the reviewers. All grant applications are judged solely on the merit of the proposal as they relate to the following four criteria:

- Novelty and Innovation
- Strength of Hypothesis
- Methods
- Potential to Impact Breast Cancer

The Foundation only funds projects that receive a superior rating based upon the above criteria. Unfortunately, we cannot fund all of the grant applications with a superior rating we receive each year. Our ultimate goal is to be able to fund all of the most promising research projects that come through our door.

Our research grant review panel consists of both scientists and advocate reviewers. Advocate reviewers come from a variety of fields – from dentistry and law to business and the arts – and share a common interest in the fight to eradicate breast cancer. Many advocate reviewers are also survivors or co-survivors.

WHAT KIND OF RESEARCH DO WE FUND?

Sixty percent of the research funded by the Komen Foundation falls under the heading of basic research – meaning the research occurs in a lab and is in the very early stages of discovery. Understanding the basic functions of breast cancer cells is important in finding new therapeutic strategies. The Komen Foundation is unique in that it's often the only source of funding for these new or novel ideas, many of which would go unfunded without our support.

Clinical and translational research, on the other hand, occurs after the basic research has been done. It's the second step in the discovery process. Clinical and translational researchers take what's been learned in the lab and apply it in a clinical setting where it directly impacts the patient.

The areas of interest funded by the Komen Foundation include basic science, improved treatments, complementary and alternative medicine, diagnostic methods, environmental factors, genetic epidemiology, diet and nutrition, psychosocial support, prevention, survivorship and imaging technologies.

In addition to basic, clinical and translational research, the Komen Foundation supports:

- A postdoctoral fellowship training program aimed at recruiting, retaining and enhancing the careers of investigators in the field of breast cancer research.
- A population specific research program that focuses on the epidemiology of breast cancer within specific populations at risk for the disease. The focus of the program is to identify unique needs, trends and barriers to breast health care among specific populations such as African American, Native Hawaiian and Pacific Islander, Asian American, Hispanic/Latino, Native American, Lesbian, Low Literacy, Breast Cancer Survivors, Women with Disabilities and other defined communities.
- An interdisciplinary breast fellowship program designed to improve the quality of care for breast cancer patients while preparing highly motivated, talented and compassionate physicians for careers devoted to serving the multi-specialty needs of the breast cancer patient. The program also offers an interdisciplinary curriculum integrated into a comprehensive program and provides special emphasis on enhancing the physician's understanding of the patient with benign and malignant breast disease while developing a better treatment environment for future patients.

RESEARCH HIGHLIGHTS FROM 2004-2005

Because of our nearly 25-year history in the fight to end breast cancer, we know there will never be one single cure to this complex disease. There will be multiple answers, treatments and preventive measures. That's why we continue to fund a variety of research projects, attacking the problem from all possible angles. What follows are some highlights of the varied research projects funded by the Komen Foundation in 2004-2005.

CAN EARLY CHANGES IN NORMAL BREAST CELLS BE REVERSED TO PREVENT BREAST CANCER?

Frederic Waldman, M.D., Ph.D.
University of California, San Francisco

The goal of this study is to better understand the earliest stages of breast cancer development so that later stage breast cancer can be prevented. This study hypothesizes that the earliest breast cell abnormalities are due to abnormal responses to hormonal stimulation, and are still reversible. However, as the DNA is damaged, the cells change shape and have the potential to progress to invasive disease. This study will define at what point in tumor evolution such changes occur. By identifying the earliest changes in cells, it may allow the development of new prevention strategies, having an enormous impact on the morbidity and mortality of breast cancer.

COULD NEWLY DISCOVERED PROTEIN STOP BREAST CANCER CELL GROWTH?


Charles Cole, Ph.D.
Dartmouth Medical School

There is a new field of genetic research involving MicroRNAs (MiRNAs), extremely small proteins that are thought to be able to block the production of cancer-causing proteins. Hundreds of MiRNAs have been discovered in the human genome. Thus, hundreds to thousands of proteins are likely to be regulated by MiRNAs. Recent leukemia and colon cancer studies indicate that specific MiRNAs contribute to the cause of some types of cancer. In this proposal, the potential roles of MiRNAs in the regulation of breast cancer are being investigated. By studying how MiRNAs work, the researchers hope to provide a foundation for future analysis in a clinical setting to diagnose, predict outcomes or even treat breast cancer.

QUALITY OF LIFE BEFORE AND AFTER A BREAST CANCER DIAGNOSIS IN OLDER WOMEN

Amy Trentham-Dietz, Ph.D., M.S.
University of Wisconsin

Due to increased early detection and more effective treatment options, breast cancer patients are living longer. As a result, quality of life issues – not just the length of survival – are receiving greater attention. Little information is known about how quality of life changes as women age, experience breast cancer diagnosis and treatment, and deal with other challenges to their health such as heart disease and diabetes. Using data collected from a previous study of older Wisconsin women with data collected by Wisconsin's statewide tumor registry, the study allows quality of life comparisons between breast cancer survivors (before and after diagnosis) and women without a personal history of breast cancer. By observing changes in quality of life in females diagnosed with breast cancer and, often, other health problems, the researchers hope to improve understanding of the complex interplay between the mental and physical health of breast cancer survivors. Based upon these findings, steps may be taken to optimize length and quality of life.



DEVELOPING A BLOOD TEST TO DETECT EARLY STAGE BREAST CANCER

Michael Tainsky, Ph.D.
Wayne State University

Researchers at Wayne State University are hoping to develop a blood test that will identify protein markers for early stage breast cancer. The test has the potential to become an easily accessible screening tool, making early detection faster and easier. The blood test will be designed for women who have no symptoms for breast cancer. It is also being developed as a new prognostic approach for staging of women with early stage ER-breast cancer, a disease from which more than 30% of women will relapse in five years.

LATINA WOMEN AND BREAST CANCER SCREENING

Ana Abraido-Lanza, Ph.D.
Columbia University

Compared with non-Latina white women, Latinas are diagnosed with breast cancer at a later stage of disease and experience a lower survival rate, indicating they do not practice early detection. Some studies suggest that Latinas are not screened for breast cancer at the same rate as non-Latina white women because of cultural values or beliefs. In contrast, other research indicates disparities in socioeconomic status and access to health care are creating barriers to screening and early detection. The objectives of the study are to address questions concerning Latinas' beliefs about breast cancer and study the relationship between these beliefs, socioeconomic status, culture, access to health care and screening. The potential outcomes of the study are to identify the most important predictors of screening, which can be used to inform health interventions and health care policies that address disparities in breast cancer between Latinas and non-Latinas.

FACTORS INFLUENCING USE OF EARLY DETECTION METHODS IN CHINA

Mei-yu Yu, M.D., Ph.D.
University of Michigan

Over the past two decades, there has been a rapid increase in breast cancer incidence rates in China, the country that is home to one-fifth of the world's women. Yet despite the huge numbers of women affected by this life-threatening disease, China has no nationally recognized breast cancer screening guidelines. About 40% of Chinese breast cancer patients die within five years because the cancer is already very advanced at diagnosis. The objective of this two-year project is to investigate the factors influencing use of early breast cancer detection among women living in urban, suburban and rural areas with varying resources for cancer detection. After analysis, researchers hope to be able to recommend scientific, systematic and practicable breast cancer screening guidelines for use in China and to propose effective strategies for promoting early breast cancer detection to Chinese women. The project has implications for fighting breast cancer in other countries with limited resources as well.

DO DIET AND LIFESTYLE PLAY A ROLE IN BREAST CANCER OUTCOMES?

Polly Newcomb, M.D., M.P.H.
University of Wisconsin Comprehensive Cancer Center

Little is known about the influence of modifiable risk factors like diet and exercise on the odds of surviving breast cancer. Using data from a group of women who were diagnosed with breast cancer between 1988 and 2002, researchers will examine post-diagnostic diet, physical activity and drug exposures as risk factors for mortality in breast cancer. Subsequent cancer diagnoses will be identified using state cancer registries, and deaths will be identified using death certificates. Approximately 728 cancer diagnoses or deaths are expected to be identified through the study. The researchers will then investigate whether diet and other aspects of lifestyle after a breast cancer diagnosis played a role in the subsequent cancers or deaths outlined in the study. This will be one of the first studies to address whether dietary and lifestyle modifications may reduce deaths from breast cancer. Ultimately, the research may offer active choices for survival after a diagnosis of breast cancer.

The mission of the Komen Foundation is to eradicate breast cancer as a life-threatening disease by advancing research, **EDUCATION**, screening and treatment.

INCREASING SURVIVAL THROUGH EDUCATION

When breast cancer is diagnosed in its earliest, most treatable stages, a person's chances for survival are greatly increased. In fact, if found before it's spread beyond the breast, the five-year survival rate is greater than 95 percent. And so, until a cure or cures are found, early detection remains our best defense against this disease. That's why the Komen Foundation is so committed to education. And one of the best vehicles we have for increasing awareness about the importance of early detection and screening is our signature event, the Komen Race for the Cure® Series.

Each year, the **Komen Race for the Cure® Series** reaches more than one million people with the message that early detection saves lives and only through a positive breast health program can breast cancer be found in its earliest, most treatable stages. The Komen Foundation's recommended three steps for good breast health include: annual screening mammography beginning at age 40; clinical breast exams every three years beginning at age 20 and annually at age 40; and monthly breast self-examinations for all women beginning by age 20.

REACHING OUT TO UNDERSERVED AUDIENCES

Despite the success of the Komen Race for the Cure® Series in increasing breast cancer awareness, there are still countless individuals – in particular minorities and other underserved populations – who do not yet understand the importance of regular screening and breast exams. One of the top priorities of the Komen Foundation is to address health disparities and provide education, outreach and support to the medically underserved and other targeted populations such as minorities, lesbians/women who partner with women, the homeless, immigrants, low-income women, young women and those living in rural areas.

Such initiatives are funded at a national and a local level. Nationally in fiscal year 2005, the Komen Foundation launched several pilot programs with the goal of reaching new audiences.

In June of 2004, the Foundation began the **Komen Co-Survivor Program** in order to recognize and help educate individuals about co-survivors – the family, friends, health care providers or colleagues who provide support for breast cancer patients through diagnosis, treatment and beyond. A pink and white ribbon was developed as part of this initiative to represent the special relationship between breast cancer survivors and their co-survivors.

In the fall of 2004, **On the Way to the Cure – The Komen College Tour** kicked off as a way to encourage young women

to begin a lifetime of positive breast health practices.

The interactive educational tour traveled to college and university campuses along the east coast in a mobile education

unit complete with computer stations, informational materials and breast self-examination guides.



The Komen Foundation also has **advisory councils** focused on addressing the breast health needs of people from different cultures and backgrounds. These councils work to reach African Americans, Hispanics/Latinas, Asian Americans and Pacific Islanders, among others, with culturally appropriate breast health information. The mission of these groups is to provide guidance and direction on programs designed to reduce the disparities in mortality of breast cancer among their respective communities.

At a local level, Komen Affiliates reached out to a variety of underserved populations in their communities. Working to eliminate barriers to breast health care and awareness within a specific population in its service area, the **Komen Greater New York City Affiliate** funded a summer education program that targeted Hasidic and Ultra-Orthodox Jewish women, providing

culturally sensitive education materials, programming and support services. Barriers to breast health care and awareness in this community include a cultural value of modesty, language, cultural concerns surrounding arranged marriages and concerns about confidentiality.

Other education initiatives are developed not only for patients, but for medical professionals and health care providers – the people responsible for delivering care. For example, the **Komen Peoria Memorial Affiliate** funded **Komen Information for the Cure™**, a specialized breast health resource collection at the University of Illinois Library of the Health Sciences-Peoria. The collection is a premier regional resource of textbooks, journals, video recordings, models and consumer health materials. Librarians present educational outreach sessions to area health care professionals, advanced nursing students specializing in women’s health and consumers to promote awareness of the collection and to instruct users how to locate and evaluate online breast cancer information.

WE ARE A TRUSTED RESOURCE

In addition to the education provided through the Race and the many other programs and services funded at national and local levels, the Komen Foundation continues to serve as a trusted source of breast health and breast cancer information for people all over the world and is instrumental in connecting people with the resources they need in their fight against breast cancer. The Foundation is an educational resource for various audiences including the general public, Komen Affiliates and staff, health care providers, corporate partners and governmental leaders. Education and outreach are accomplished through the following means:

- Web site, www.komen.org
- National Toll-Free Breast Care Helpline, 1.800 I’M AWARE®
- Semi-annual print newsletter, *Frontline* (reaches one million people with each issue)
- Monthly e-newsletter, *KomenLink*
- Conferences and trainings
- Print and audio-visual educational materials
- Partnerships with corporate and community groups



The mission of the Komen Foundation is to eradicate breast cancer as a life-threatening disease by advancing research, education, **SCREENING** and treatment.

ACCESS IS KEY TO SURVIVAL

Breast cancer is one of the most common cancers among women living in the United States. It is the most frequently diagnosed cancer among nearly every racial and ethnic group, including African American, American Indian/Alaska Native, Asian American/Pacific Islander and Hispanic/Latina women. Race is not considered a factor that might increase a woman's chance of getting breast cancer. Access to health care and participation in screening such as mammography and clinical breast exams may explain at least some of the racial and ethnic differences in breast cancer mortality rates. Because a late stage cancer diagnosis has a poor prognosis, the Komen Foundation funds a multitude of screening programs and services in local communities.

For example, a breast care program funded by the **Komen Central Oklahoma Affiliate** was developed to improve breast health services to Native American women. Since the program started in 2004, 24.7% more Native American women living in the area received a mammogram at the Oklahoma City Indian Clinic. Statistically, Native American women have a lower breast cancer survival rate than other racial or ethnic groups because they tend to have less access to and use of early detection services. To combat this particular problem, the clinic now provides improved screening and mammography services and, just as important, provides education and immediate support to those women who receive a breast cancer diagnosis. By increasing education, expanding outreach, targeting younger women and screening all female patients, the clinic has helped decrease the mortality rate of Native American women diagnosed with breast cancer in Central Oklahoma.

Similar programs and services are being funded by Komen Affiliates across the country, with dollars being granted to help those who need it most. Based on a detailed community profile, Komen Affiliates identify gaps in their communities and provide funding for missing services, often collaborating with other groups like the YWCA and the American Cancer Society. In addition to funding low- or no-cost mammograms and clinical breast exams, Komen Affiliates fund programs that help eliminate barriers to care such as language, cultural differences, transportation, lack of insurance and childcare.

Nationally, the Komen Foundation continues to push for increased federal funding for screening services for women with little or no health insurance through its grassroots public policy program, **Komen Champions for the Cure™**. One of the top priorities for Komen Champions is the reauthorization of the National Breast and Cervical Cancer Early Detection



Program (NBCCEDP), which provides breast cancer screening, outreach and case management services for women with little or no health

insurance. To date, this program has screened more than 2.1 million women and provided more than five million clinical breast exams.

Through the NBCCEDP, more than 17,000 cases of breast cancer have been diagnosed and disparities in screening have been reduced for racial and ethnic minority women. Yet, the current NBCCEDP funding level only covers 18 to 20 percent of eligible women, which means that four out of five eligible women are not being served. Through the Foundation's public policy Web site, www.actnowendbreastcancer.org, Komen Champions urge members of Congress and other policy makers to increase funding for this life-saving program.



LOOKING TO THE FUTURE

While mammography, clinical breast exam and breast self-exam remain the current standards in breast cancer screening, the Komen Foundation is committed to finding improved methods. As such, the Foundation funds a variety of research grants in the area of imaging technology, as well as other innovative approaches to screening, diagnosis and prognosis. For example, **Saraswati Sukumar, Ph.D.**, a Komen research grantee at the Johns Hopkins Kimmel Cancer Center, is working with a team of investigators to determine whether a sophisticated test using a very small sample of breast nipple fluid could provide relatively quick answers to a number of big cancer questions, including the two most urgent ones: “Do I have cancer?” and “Will I get cancer?”

Similarly, researchers at the University of Wyoming – led by principal investigator **Beverly Sullivan, Ph.D.** – are exploring a simple saliva test that could possibly determine whether a patient has a biomarker for an aggressive form of breast cancer. The research to perfect the technique was funded in part by the Komen Foundation. The project is significant for its potential to make “even earlier” detection of cancer and earlier medical intervention possible.

Whatever future innovations occur, it will remain the job of the Komen Foundation to ensure the new methods, technologies, tests and procedures reach the people who need them. New screening technologies are only effective if they are available and accessible to all women, everywhere.

The mission of the Komen Foundation is to eradicate breast cancer as a life-threatening disease by advancing research, education, screening and **TREATMENT**.

IMPROVING TREATMENT OPTIONS

The ultimate pinnacle in our fight against breast cancer is to find a way or ways to prevent the disease from occurring in the first place. However, until breast cancer can be prevented, we remain committed to funding research that leads to improved treatment options for those diagnosed with the disease today. Improved treatments can mean a variety of things, from less invasive procedures or surgeries to new drugs with fewer side effects to better outcomes. One example of a research project currently funded by the Komen Foundation that has the potential to improve treatment methods is taking place at the University of Wisconsin by **Tara Breslin, M.D.**

Dr. Breslin and team have developed a new way to ensure that all breast cancer tissue is removed during surgery. Achieving complete removal of all tumor cells with a rim of normal tissue surrounding them (the surgical margin) is crucial to successful surgery and a low recurrence rate. Currently, there is no way to ensure a surgeon has “gotten it all” in the operating room. Tissue samples are analyzed in a lab after surgery and if the results indicate additional cancer, the patient typically undergoes another surgery. Dr. Breslin’s pilot study offers a new method for determining if the margins are clear right in the operating room, thus eliminating the potential need for a second surgery.



INCREASING ACCESS

And while innovations are occurring across the spectrum of care, it remains imperative that everyone have access to the treatment they need regardless of race, age, language, ethnic background, insurance or financial status. One of the best ways our Affiliates have found to ensure that people who are diagnosed with breast cancer receive the care they need is through patient navigator programs. One example of a successful navigator program is being funded by the **Komen Puget Sound Affiliate**. At Harborview Medical Center in Seattle, a breast cancer buddy program was initiated that partners survivors, nursing students and staff with patients – many of whom do not speak English – as they navigate the health care system and access available community support. Navigator programs like this one are tailored for each specific community, taking into account the barriers to care that often exist.

In addition to navigator programs, several Komen Affiliates help promote participation in clinical trials. The **Komen Maryland Affiliate** funds a program at Shore Regional Cancer Center that employs a clinical trials research nurse to educate physicians, members of the community and potential candidates about clinical trials and the benefits of participation. After candidates are identified, the nurse assists in the enrollment process and in data management. The cancer program of Shore Health System currently has six breast cancer clinical trials open with 22 women enrolled in these trials. The emphasis of the program is to increase the enrollment of all eligible women, but with a continuing focus on educating members of the African American community about clinical trials and the need for involvement. The program builds on previously established relationships with community leaders and clergy of the African American community.

EASING FINANCIAL FEARS

Having breast cancer can be both life-threatening and expensive. Medical treatment and hospital stays for surgery are costly, especially if you are uninsured. Even if you have insurance, the costs can be daunting. In order to help ease the financial burden associated with breast cancer, the Komen Foundation has partnered with CancerCare, a not-for-profit organization dedicated to providing support to cancer patients and their loved ones. The program, called **Linking A.R.M.S.™: Assistance & Resources Made Simple**, awards grants to economically disadvantaged breast cancer patients to cover the costs associated with treatment medications, lymphedema support and supplies, and durable medical equipment.

Similarly, Komen Affiliates work with local organizations in their own communities to help fill existing gaps in breast health and breast cancer care. For example, the **Komen Denver Metropolitan Affiliate** funds a grant to Sense of Security, an organization that supports the entire state of Colorado by providing breast cancer patients with comprehensive, sustained financial assistance through the duration of treatment.

FINANCIALS

The Komen Foundation is committed to making a real difference in the lives of all those affected by breast cancer. As part of our commitment, we are extremely careful when it comes to spending the dollars we raise, dedicating as much money as possible to the fight against breast cancer. By relying on a team of volunteers and keeping administrative and fundraising expenses extremely low (16 percent), in fiscal year 2005 the Foundation was able to invest \$136 million in grants and programs related to breast cancer research, education, screening and treatment. The Foundation currently has grants payable of more than \$110 million, representing commitments made to grantees for research, education, screening and treatment. To ensure these dollars are used as intended, the Foundation makes periodic payments to the grantees based on successful progress reporting.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As of March 31, 2005 and 2004

2004

2005

ASSETS:

Cash and investments	\$ 109,792,752	\$ 148,068,737
Receivables	24,248,652	31,407,095
Net property, plant and equipment	4,350,104	2,810,489
Other assets	2,072,009	3,556,080
Total Assets	<u>\$ 140,463,517</u>	<u>\$ 185,842,401</u>

LIABILITIES:

Accounts payable and accrued expenses	\$ 7,354,456	\$ 9,875,850
Notes payable	1,433,333	—
Grants payable	75,217,782	110,763,979
Total Liabilities	<u>84,005,571</u>	<u>120,639,829</u>

Total Net Assets	<u>56,457,946</u>	<u>65,202,572</u>
Total Liabilities and Net Assets	<u>\$ 140,463,517</u>	<u>\$ 185,842,401</u>

FINANCIALS

For the fiscal year ending March 31, 2005, the Komen Foundation recognized more than \$231 million in cash and in-kind revenues to fight breast cancer, thanks in large part to the hard work of the Affiliate Network and volunteers who helped generate nearly \$135 million through the Foundation's signature series of events, the Komen Race for the Cure®. The Foundation received in-kind gifts (contributed goods and services) including advertising, legal services and Race giveaways like water, bananas and yogurt, that totaled more than \$51 million in fiscal year 2005. Because of these donated goods and services, the Foundation was able to spend 81 cents of every dollar raised on research, education, screening and treatment.

CONSOLIDATED STATEMENT OF ACTIVITIES

Years ended March 31, 2005 and 2004	2004	2005	Where Does Your Dollar Go?	
			2005 Value of Contributed Goods & Services	Year Ended March 31, 2005 Net
Public support and revenue:				
Contributions	\$ 77,231,582	\$ 87,128,465		
Komen Race for the Cure®	96,913,909	134,562,521		
Other public support and revenue	8,991,270	9,985,695		
Total gross revenue	183,136,761	231,676,681	\$ 51,863,869	\$ 179,812,812
Less:				
Komen Race for the Cure® direct costs	(24,340,898)	(22,335,276)	(11,187,034)	(11,148,242)
Net public support and revenue	158,795,863	209,341,405	40,676,835	168,664,570
Expenses:				
Program services:				
Research and awards	39,230,259	57,795,729		
Public health education	44,607,887	59,017,665		
Health screening services	17,438,937	20,314,122		
Treatment services	8,736,906	12,369,410		
Total program services	110,013,989	149,496,926	13,647,218	135,849,707
Supporting services:	43,341,156	51,099,853	24,290,579	26,809,274
Total expenses	153,355,145	200,596,779		
Change in net assets	5,440,718	8,744,627	2,739,038	6,005,589
Net assets beginning of year	51,017,228	56,457,946		
Net assets end of year	\$ 56,457,946	\$ 65,202,573		

81¢ of every dollar raised was spent on mission programs and services.

Ernst & Young, LLP performed the 2004-2005 consolidated audits for the Foundation. Audited financial statements are available upon request.

SUPPORT

Today, there are almost as many ways to get involved in the fight against breast cancer as there are people. There is truly something for everyone. Support comes in a variety of shapes and sizes and goes well beyond monetary gifts. At the Komen Foundation, support can mean anything from being an advocate for increased federal funding for screening programs through Komen Champions for the Cure™, to donating radio and TV air time to help promote a local Komen Race for the Cure® event.

Last year, Nancy's promise to Suzy continued to be realized through the work of more than 75,000 volunteers in the Komen Affiliate Network – people who gave their time freely in large and small ways to support the mission. They organized Races, educated people from all walks of life about the importance of early detection, planned Pink Tie Balls and granted millions of dollars in their local communities for breast cancer education, screening and treatment.

The promise was also demonstrated by more than one million people who participated in Komen Race for the Cure® events around the country, and by every person who pledged to support those who ran, walked or jogged for a cure.

The promise was furthered by individual donors who honored survivors, loved ones or those who lost their lives too early because of the disease. And it was fostered by every worker who paid \$5 to wear jeans on Lee National Denim Day® and those who walked 60 miles over three days in support of the Breast Cancer 3-Day.



In addition, the Komen Foundation benefited from in-kind gifts such as advertising, legal services and Race giveaways like water, bananas and yogurt. Corporate partners developed specific programs and promotions geared at generating money and awareness for the fight against breast cancer, providing an opportunity for individuals to join in the fight against breast cancer in a way that is meaningful to them.

As such, the Komen Foundation is dedicated to setting new standards for creative collaboration in the fight against breast cancer. At the national level, the Komen Foundation has three levels of support from industry leaders and dedicated corporate citizens, including our Million Dollar Council, Corporate Partners and National Series Sponsors of the Komen Race for the Cure®.

The **Komen Million Dollar Council** is a special group of cause partners. In addition to a financial contribution of at least \$1 million, each of these organizations has found new and innovative ways to spread two important messages: early detection saves lives and only through research can we find a cure. They are a tremendous help in the fight against breast cancer and we thank them for their generous commitment and support.

American Airlines began its partnership with the Komen Foundation in 1992. American Airlines is the official airline carrier of the Foundation, is a National Series Sponsor of the Komen Race for the Cure® and also hosts the annual American Airlines Celebrity Golf Weekend which benefits the Foundation.



BMW of North America, Inc. has partnered with the Komen Foundation through the BMW Ultimate Drive since 1997. The program features two cross-country caravans of specially marked BMWs that guests are invited to test drive at BMW retail centers across the nation. For each mile driven, BMW contributes \$1 to the Foundation.



Each year, the **Carlisle Collection, Ltd.** creates a special "Fabric of Hope" scarf to promote the Komen Foundation's efforts in the fight against breast cancer. The scarf is a gift to anyone who makes a \$125 or more donation to the Komen Foundation through a Carlisle consultant.

CARLISLE

Ford Credit and NASCAR driver **Dale Jarrett** and his wife, **Kelley**, have been longtime supporters of the fight against breast cancer. In support of their partnership, Ford Credit made donations to the Foundation based on Dale Jarrett's performance at NASCAR Nextel Cup events: \$10,000 for each first place finish; \$7,500 for each second; \$5,000 for each third; and \$5,000 for each pole position.



Ford Division has served as a National Series Sponsor of the Komen Race for the Cure® since 1994. In addition, Ford partners with designers to create a special breast cancer awareness scarf each year. Net proceeds from scarf sales (85 percent of each sale) are donated to the Foundation. Ford is the exclusive automotive sponsor of the Komen Race for the Cure® Series.



In 1999, **Hallmark Gold Crown® Stores** launched **Cards for the Cure®**, a program featuring a free, specially designed greeting card created by a Hallmark artist who is also a breast cancer survivor. Each year, Hallmark also creates a special holiday Angel Ornament with \$2 from each sale donated to the Foundation.




Since 1996, **Kellogg Company** has supported the Komen Race for the Cure® Series and other programs. Driving awareness and support of the Komen Foundation's mission is at the core of the Kellogg Company's sponsorship and its "Keep the Promise" program.



Launched in 2001, **Cook for the Cure®** raises funds for the Foundation through the purchase of select **KitchenAid®** products, special fundraising events, cooking classes and a grassroots program that helps supporters throw their own Cook for the Cure® fundraising dinner parties.



Since 1996, on one day in October, millions of Americans wear denim in support of the fight against breast cancer. Companies, organizations and schools nationwide participate annually in **Lee National Denim Day®** by encouraging employees, members, staff and students to wear denim in exchange for a \$5 donation to the Komen Foundation. **Lee National Denim Day®** is the largest single day fundraiser for breast cancer research, education, screening and treatment. It is the most successful program of its kind – having raised more than \$52 million since 1996, with the Komen Foundation receiving 100 percent of all donations that are made.



The Val Skinner Foundation was founded by Ladies Professional Golf Association (LPGA) Touring Professional **Val Skinner** in 1993 after close friend and fellow LPGA Player **Heather Farr** died of breast cancer. Thanks to the LIFE Event (LPGA Pros In the Fight to Eradicate Breast Cancer), a premier golf event featuring current and past LPGA players, \$1.25 million has been donated to the Foundation for breast cancer programs targeted toward young women.



Mohawk Industries, Inc., is the manufacturer of Durkan Commercial, Karastan Contract and Durkan Patterned commercial carpets. When these products are specified by commercial interior designers, **The Mohawk Group** Mohawk donates \$.25 per square yard sold in its commercial market to the Foundation. Similarly, Mohawk Residential Flooring donates 10 cents per yard to the Foundation on select Mohawk residential carpet.

New Balance Athletic Shoe, Inc. has been associated with the Komen Race for the Cure® Series since 1989 and has served as a National Series Sponsor since 1991. Through its Lace Up for the Cure® program, for every postcard returned from a \$25 or more New Balance Pink Ribbon Collection purchase, New Balance makes a \$5 donation to the Komen Foundation up to \$125,000.



Since 1997, each October **Pier 1 Imports, Inc.** sells a commemorative Komen Candle with 25 percent of the purchase price from sales donated to the Foundation. Pier 1 has partnered with the **Pier 1 imports®** Foundation since 1991.



Started in 1996, **Rally For A Cure®** is the first and largest national golf club program of its kind. Designed as a way to educate amateur female golfers about breast health and breast cancer, the program also raises funds for the Foundation through license fees and ancillary donations.



RE/MAX International supports the Foundation through its co-sponsorship of the Komen Race for the Cure® Series Breast Cancer Survivor Recognition Program. At each event, RE/MAX honors breast cancer survivors by providing signature pink T-shirts and caps for survivors to wear. Race participants also receive “In Memory of” or “In Celebration of” back signs to honor a friend or loved one.



The Komen Foundation has received support from **Titleist**, **Cobra** and **FootJoy Worldwide** for 10 years. These companies provide golfers with a distinctive reminder that early detection is an important key to survival by featuring the pink ribbon logo on Titleist and Pinnacle golf balls. In conjunction with Rally for a Cure®, sponsored by *Golf For Women* magazine, Titleist provides a pink ribbon custom-imprinted golf ball for every golfer who “hits the green.”



The Women’s International Bowling Congress (WIBC) sponsors **Bowl for the Cure®**, a nationwide initiative designed to increase breast cancer awareness and raise funds for the Komen Foundation and the fight against breast cancer. Participating bowling leagues designate a bowling session of their choice as a Bowl for the Cure® event and bowlers donate a “penny per pin” (or any amount they wish) during the designated session.



Wyndham Hotels & Resorts is the National Hotel Partner of the Foundation. In 1999, Wyndham began observing National Breast Cancer Awareness Month with its **Dream for the Cure®** program to help support breast cancer research, education, screening and treatment. Through Dream for the Cure®, guests receive specially designed pillow cards in their room, and are provided an opportunity to make a donation directly to the Foundation.



Yoplait USA has served as National Presenting Sponsor of the Komen Race for the Cure® Series since 2001. Yoplait was a National Series Sponsor of the Komen Race for the Cure® in 2000 and served as the National Volunteer Program Sponsor of the Race Series in 1999. In addition to supporting the Race Series, Yoplait sponsors the highly successful **Save Lids to Save Lives™** program, which takes place throughout September and October each year. For each pink lid mailed in by customers, Yoplait donates 10 cents to the Komen Foundation (up to \$1.2 million).



Zeta Tau Alpha (ZTA) became the first sponsor of the Breast Cancer Survivor Recognition Program at Komen Race for the Cure® events in 1992. As part of its co-sponsorship, ZTA provides “In Memory of” and “In Honor of” back signs to Race participants and pink hats and t-shirts to breast cancer survivors. Additionally, Zetas participate in the ZTA “Don’t be a Fool... Do Monthly Breast Self-Examination” campaign on April 1 each year.



CORPORATE PARTNERS

- Belk Department Stores
- Blockbuster
- Bosca
- Boston Market
- Breeder's Choice
- Brinker International, Inc.
- CESAR® Food for Small Dogs
- Crest Uniforms
- Curvation
- Deluxe Corporation
- DSW
- eBags.com
- Interiors by Decorating Den
- Lean Cuisine
- Lladró
- Love It, LLC
- Ladies Professional Golf Association (LPGA)
- Lowe's Companies, Inc.
- M&M's Chocolate Candies
- Napa Valley Trading Company
- Payless Shoe Source
- Proflowers.com
- Quilted Northern Ultra®
- Republic of Tea
- Sherwin Williams
- Tumi
- Wacoal America
- Women's National Basketball Association (WNBA)
- WorldWinner.com

NATIONAL SERIES SPONSORS OF THE KOMEN RACE FOR THE CURE®

The Komen Race for the Cure® Series is privileged to have the generous support of nine major corporations and one of the nation's largest fraternal organizations. Each Race Series Sponsor provides a cash commitment to cover a large portion of the expenses associated with hosting a national series of more than 100 Race events. Just a few of the expenses they help cover include Race T-shirts for all participants, survivors and volunteers, and national advertising. In addition, each sponsor develops and implements programs, promotions and activities to support Races in their local communities. Examples include airline tickets, gift certificates, local advertising, local fundraising support, product samples and special product sales.

NATIONAL PRESENTING SPONSOR

- Yoplait

NATIONAL SERIES SPONSORS

- American Airlines
- Ford
- Coldwater Creek
- Kellogg's
- New Balance
- Quilted Northern Ultra®
- Silk Soymilk

BREAST CANCER SURVIVOR

RECOGNITION PROGRAM

- RE/MAX
- Zeta Tau Alpha Fraternity

The Susan G. Komen Breast Cancer Foundation



Presented by 

NATIONAL SERIES SPONSORS:



NATIONAL SERIES HONORARY CHAIR: FRANCIE LARRIEU SMITH

RESEARCH GRANTS

The Komen Foundation funds a variety of research projects at leading institutions around the globe. Combined with the funding of community outreach programs that provide much-needed education, screening and treatment services for the medically underserved, the Komen Foundation is also committed to helping find a cure or cures for breast cancer and to discovering its causes and methods of prevention. We proudly recognize the research grantees listed on the following pages for their dedication to creating a world without breast cancer. They are truly *a promise in action*.

BIOLOGY OF BREAST CANCER

Nancy Phillips, M.D.

Saint Louis University
*A Candidate Breast and Ovarian Tumor
Suppressor Gene on Chromosome 17p13.3*

Stacy Blain, Ph.D.

SUNY Downstate Medical Center
*A TGF- β Responsive Gene Therapy Vector
(TRGT) that Specifically Kills Metastatic
Breast Cancer*

Rachel Hazan, Ph.D.

Albert Einstein College of Medicine of
Yeshiva University
*An Investigation of p21CIP1 Function
During Breast Cancer Metastasis*

Michiko Fukuda, Ph.D.

The Burnham Institute
*Analysis of O-glycans Involved in Lung
Metastasis of Breast Cancer*

Melinda Sanders, M.D.

Vanderbilt University School of Medicine
*Analysis of Proteomic Patterns in Breast Cancer
and Associated Tumor Stroma*

Eliot Rosen, M.D., Ph.D.

Georgetown University
*BRCA1 Regulation of Progesterone Receptor
Function in Breast Cancer*

Charlotte Kuperwasser, Ph.D.

Tufts University School of Medicine
*Breast Cancer Stem Cells in the Formation of
Bone Metastasis*

Richard Baer, Ph.D.

Columbia University
*Cell Cycle Checkpoint Functions of the
BRCA1/BARD1 Tumor Suppressor Complex*

Kum Kum Khanna, Ph.D.

The Queensland Institute of
Medical Research
*Characterization of a Novel Protein
Implicated in Breast Cancer Progression*

Irene Kazhdan, M.D., Ph.D.

University of Texas Health Science Center at
San Antonio
*Characterization of Surviving Contribution to
ErbB2-Mediated Drug Resistance*

Glen Barber, Ph.D.

University of Miami
*Characterization of VSV Oncolytic Activity in
Breast Cancer Model Systems*

Pamel Cowin, Ph.D.

New York University School of Medicine
*Characterizing the Beta-Catenin Transgenic
Model of Hormone-Independent Breast Cancer*

Anne Villeneuve, Ph.D.

Stanford University
*Chromatin and the Regulation of DNA
Double-Strand Breaks*

Andrei Goga, M.D., Ph.D.

University of California, San Francisco
*Conditional Loss of the Mitotic Spindle
Checkpoint in Chromosomal Instability and
Tumorigenesis*

Frank Church, Ph.D.

University of North Carolina at Chapel Hill
*Cooperation of Adipocytes with Breast Cancer
Cells Promotes an Invasive Phenotype*

Dipali Sharma, Ph.D.

Emory University
*Cross-Talk Between ER Coregulators and
Growth Factor Pathways in Breast Cancer
Endocrine Resistance*

Matthew Bogoy, Ph.D.

Stanford University School of Medicine
*Crosstalk Between Extrinsic and Intrinsic
Caspase Activation Pathways in Doxorubicin-
Mediated Sensitization of Breast Cancer Cells to
TRAIL-Induced Apoptosis*

Chenguang Wang, Ph.D.

Georgetown University
*Cyclin D1 Regulation of Nuclear Receptor
Function*

Jason Weber, Ph.D.

Washington University
*Defining the Oncogenic Role of NPM/B23
Through Ribosome Biology*

Patrick Sung, Ph.D.

Yale University
*Delineation of the role of the tumor suppressor
BRCA2 in homologous recombination and
DNA repair*

Mesut Muyan, D.V.M., Ph.D.

University of Rochester
*Designer Transcription Repressors: Toward the
Treatment of Endocrine Resistant Breast Cancers*

Kevin Yarema, Ph.D.

The Johns Hopkins University
*Development of Glycosylation-based Therapies
for Breast Cancer: Targeting Sialic Acid-
Mediated Metastasis with Metabolic Analogs
that Modulate Sialoside Biosynthesis*

Mark Watson, M.D., Ph.D.

Washington University
*Directed Kinome Resequencing to Define
New Targeted Therapies for “Basal-Like”
Breast Cancer*

Max Wicha, M.D.

University of Michigan
*Disregulation of Stem Cell Self-renewal in
Breast Cancer Development*

David Crowe, Ph.D.

University of Southern California
*DNA Repair and the Etiology of Estrogen
Receptor Positive Breast Cancer*

Alan Houghton, M.D.

Sloan-Kettering Institute for Cancer Research
*DNA Vaccines Against Breast Cancer: Synergy
Through Targeting Both Tumor Cells and
Tumor Stroma*

Asit De, Ph.D.

University of Rochester Medical Center
*Does Heat Shock Protein 27 (Hsp27) Play Any
Immunomodulatory Role in Breast Cancer?*

Didier Dreau, Ph.D.

University of North Carolina at Charlotte
*Endothelin-1 Effects on the Development of
Breast Cancer Bone Metastases*

Kathy Miller, M.D.

Indiana University
EphA2, a Novel Target for Breast Cancer Therapy

Victor Levenson, M.D., Ph.D.

Northwestern University
*Genes Providing Resistance to Tamoxifen:
Development and Validation of Clinical
Biomarkers*

Robert Schneider, Ph.D.

New York University School of Medicine
Genetic Understanding of Locally Advanced Breast Cancer

Vassilios Papadopoulos, Ph.D.

Georgetown University Medical Center
Ginkgo Biloba Extract in the Treatment of Human Breast Cancer

Jeffrey Rosen, Ph.D.

Baylor College of Medicine
Identification and Characterization of Breast Cancer Stem Cells

Anait Levenson, M.D., Ph.D.

Northwestern University
Identification of Estrogen Regulated Metastasis-Associated Genes Involved in Breast Cancer Bone Metastases

Philip Cole, M.D., Ph.D.

Johns Hopkins University
Identification of Substrates of the Her2/neu Tyrosine Kinase in Breast Cancer Cell Lines using Chemical Rescue of a Her2/neu Catalytic Loop Point Mutation

Charles Cole, Ph.D.

Dartmouth Medical School
Identification, Expression Profiling and Functional Analysis of MicroRNAs in Breast Cancer

William Holloman, Ph.D.

Weill Medical College of Cornell University
Incidence of DSS1 Mutations in High Risk Breast Cancer Families

Ruben-Rene Gonzalez, Ph.D.

Boston Biomedical Research Institute
Inhibition of Leptin Signaling for Treatment of Breast Cancer

Kurtz Paulson, Ph.D.

Tufts-New England Medical Center
Invasive Breast Cancer: HBP1 as a Clinical and Molecular Predictor

Neil Clipstone, Ph.D.

Loyola University in Chicago
Investigating the Role of the NFAT Signaling Pathway in Mammary Tumorigenesis

Alan D'Andrea, M.D.

Dana-Farber Cancer Institute
Investigation of the Role Played by BRCA1 in the Activation of FANCD2 Following Chemotherapy Induced DNA Damage

Robert Clarke, Ph.D.

Georgetown University, Lombardi Comprehensive Cancer Center
IRF-1-Dependent Apoptosis and Antiestrogen Sensitivity in Breast Cancer

Rainer Brachmann, M.D.

University of California, Irvine
LDP1 Directly Links the Tumor Suppressor Protein P53 to Iron Metabolism

Ajay Rana, Ph.D.

Texas A&M University
Health Science Center
MLK3 Meets Pak1 in Breast Cancer: A Prognostic Factor and a Therapeutics Target

Gary Sahagian, Ph.D.

Tufts University School of Medicine
Molecular Basis of Bone Metastasis in Breast Cancer

Gary Luker, M.D.

University of Michigan Medical School
Molecular Imaging of CXCR4 in Breast Cancer: Effects on Tumor Angiogenesis

Yibin Kang, Ph.D.

Princeton University
Molecular Mechanisms Underlying Aggressive Conversion of Dormant Breast Cancer Metastasis

Rajeev Samant, Ph.D.

University of South Alabama
MRJ: A Molecular Switch for Cell Cycle and Cancer Metastasis

Alan Hall, Ph.D.

University College London, MRC-LMCB
Notch Regulation of Epithelial-Mesenchymal Transition During Wound Healing and Migration of Mammary Epithelial Cells

Fred Schaufele, Ph.D.

University of California, San Francisco
Novel Imaging Techniques to Compare Estrogen Receptor Structure in Tumors and Normal Tissues of Intact Living Animals

Richard Klemke, Ph.D.

The Scripps Research Institute
Novel Signaling Mechanisms of CXCR4-induced Chemotaxis

Mark Waltham, Ph.D.

St. Vincent's Institute of Medical Research
Novel Targeting of TGFβ in Osteolytic Metastasis

Frederic Waldman, M.D., Ph.D.

University of California, San Francisco
Phenotypic and Genomic Alterations in Epithelial Atypia and In Situ Breast Neoplasia

Eva Schmelz, Ph.D.

Wayne State University
Prevention of Breast Cancer by Sphingolipids: Importance of EGFR Regulation

Benjamin Cravatt, Ph.D.

The Scripps Research Institute
Profiling Enzyme Activities in Human Breast Cancer

Charles Clevenger, M.D., Ph.D.

Northwestern University
Prolyl Isomerase Function in Breast Cancer

Mark Moasser, M.D.

University of California, San Francisco
Promiscuous Her3 signaling: A New Target in the Treatment of Breast Cancer

Mary Helen Barcellos-Hoff, Ph.D.

Lawrence Berkeley National Labs
Radiation and TGF Beta as Mediators of Stromal Activation in Breast Carcinogenesis

Serge Fuchs, M.D., Ph.D.

University of Pennsylvania
Regulation of Prolactin Receptor Stability and Signaling by Ras Oncogene

Brian Dynlacht, Ph.D.

New York University School of Medicine
Regulation of the Cellular Senescence Program by RB Proteins

George Barnes, Ph.D.

Boston University
Regulation of the Preferential Skeletal Metastasis of Breast Cancers by Runx2

Suzanne Ostrand-Rosenberg, Ph.D.

University of Maryland Baltimore County
Reversal of Tumor-Induced Immune Suppression

Patrick Sung, Ph.D.

Yale University
Role of BRCA2 in Homology-Directed Repair of DNA Breaks

JoAnn Trejo, Ph.D.

University of North Carolina at Chapel Hill
Role of Coagulant Proteases in Breast Cancer Cell Invasion

Said Akli, Ph.D.

University of Texas
M.D. Anderson Cancer Center
Role of Cyclin E in the Presence or Absence of CDK2 in Breast Tumorigenesis

Laura Benjamin, Ph.D.

Beth Israel Deaconess Medical Center/
Harvard Medical School
Role of Small GTPase RhoB in Breast Tumorigenesis

Jianlin Gong, M.D.

Boston University
Role of Telomerase and Telomeres in the Tumorigenesis of Breast Cancer

Henning Willers, M.D.

Massachusetts General Hospital
Role of the BRCA1-FANCD2 Pathway in the Repair of DNA Double-Strand Breaks by Non-Homologous Recombination

- Bassem Haddad, M.D.**
Georgetown University
Role of the Breast Cancer Cell 2 (BRCC2) Tumor Suppressor Gene in Early-Onset Breast Cancer
- Toshihiro Shioda, M.D., Ph.D.**
Massachusetts General Hospital
Roles of BIK Apoptosis-inducing Protein in Breast Cancer
- Robert Abraham, Ph.D.**
The Burnham Institute
Roles of Chk1 Kinase in Breast Cancer Etiology and Therapy
- Keith Burridge, Ph.D.**
University of North Carolina at Chapel Hill
Scaffolding Proteins and Rho Signaling in Breast Cancer
- Rakesh Srivastava, Ph.D.**
University of Maryland
Significance of Histone Deacetylase Inhibitors in Breast Cancer
- Morag Park, Ph.D.**
McGill University
Significance of Shc-dependent Signaling Pathways in Breast Cancer Angiogenesis
- Anna Riegel, Ph.D.**
Lombardi Cancer Center
Small animal ultrasound to examine the role of AIB1 and its isoform in estrogen receptor alpha-initiated preneoplasia and DCIS
- Ahmed Sultan, Ph.D.**
Georgetown University
Stat5 a Novel Therapeutic Protein for Breast Cancer Invasion and Mesenchymal Transition Regulation
- Corinne Silva, Ph.D.**
University of Virginia
STAT5 as a Common Mediator of Estrogen and Growth Factor Signaling in Breast Cancer
- Bruce Spiegelman, Ph.D.**
Dana-Farber Cancer Institute
Structural and Biochemical Characterization of PGC-1 α Coactivation of the Tumor Suppressor Protein P53
- Phoebe Rice, Ph.D.**
University of Chicago
Structure and Biochemistry of the Homologous DNA Recombinase Rad51
- Marilyn Resh, Ph.D.**
Memorial Sloan-Kettering Cancer Center
Synergism Between c-Src and EGFR Intracellular Trafficking in Breast Cancer
- H. Earl Ruley, Ph.D.**
Vanderbilt University Medical Center
Tamoxifen Response Pathway Characterization by Reversible Gene Entrapment of Breast Cancer Cells
- Todd Skaar, Ph.D.**
Indiana University
Targeting Indoleamine 2,3-Dioxygenase to Block Breast Cancer Metastasis
- Jeffrey Singer, Ph.D.**
Brown University
The Cul3 Ubiquitin Ligase Is A Potential Marker for Breast Epithelial Tumorigenesis
- Myles Brown, M.D.**
Dana-Farber Cancer Institute
The Differential Effects of Estrogen on Gene Regulation and Apoptosis in the Breast and Bone
- Rachel Hazan, Ph.D.**
Albert Einstein College of Medicine of Yeshiva University
The FGF Receptor is a Target for N-Cadherin in Breast Cancer Invasion
- Leslie Shaw, Ph.D.**
University of Massachusetts Medical School
The Role of Shp2 in the Alpha 6 Beta 4 Integrin-dependent Metastasis
- Lisa Butler, Ph.D.**
University of Adelaide
The Role of Androgen Receptor Signaling in the Breast: Potential Disruption by Synthetic Progestins Used in Hormone Replacement Therapy
- Gina Chung, M.D.**
Yale University
The Role of Chemokines and Their Receptors in Breast Cancer
- Gustavo Leone, Ph.D.**
Ohio State University
Research Foundation
The Role of E2F3 in Breast Cancer
- John Price, Ph.D.**
St Vincent's Institute of Medical Research
The Role of HSF-1 in the Enhancement of Osteoclastogenesis and Bone Metastasis by the Hsp90 Inhibitor, 17-AAG
- Ceshi Chen, Ph.D.**
Emory University
The Role of KLF5 Transcription Factor Degradation in Breast Cancer
- John Lydon, Ph.D.**
Baylor College of Medicine
The Role of Osteoprotegerin-Ligand in Progesterone-Dependent Mammary Morphogenesis and Tumorigenesis
- Heide Ford, Ph.D.**
University of Colorado
Health Sciences Center
The Role of Six1, and its Target Cyclin A1, in Breast Cancer
- Robert Roeder, Ph.D.**
The Rockefeller University
The Role of TRAP220 in Estrogen Receptor-Dependent Function and in Mammary Gland Development and Neoplasia
- Andrew Lane, Ph.D.**
University of Louisville
The Roles Of Selenium Compounds In Inhibiting Proliferation And Metastasis Of Breast Cancer
- Ana Soto, M.D.**
Tufts University
The Stroma as a Gatekeeper of Tumor Development
- Gerard Blobe, M.D., Ph.D.**
Duke University
The Type III TGF-Beta Receptor as a Candidate Tumor Suppressor Gene in Breast Cancer
- Masoud Manjili, Ph.D.**
Virginia Commonwealth University
Toward Complete Inhibition of Spontaneous Mammary Tumors by a Combinational HSP110-HER-2/neu Chaperone Vaccine
- Heather Cunliffe, Ph.D.**
Translational Genomics Research Institute
Transcription Profiling of Protein Kinase C Activation in a Panel of Breast Cancer Cells Identifies a Strong Genetic Signature Consistent with Invasion and Metastasis
- Garry Larson, Ph.D.**
Beckman Research Institute of the City of Hope
Transcriptional Gene Interactions in Breast Cancer: Discovery and Analysis of Risk-Associated Regulatory Polymorphisms Combining Microarray and Linkage Analyses
- Janet Price, Ph.D.**
University of Texas
M.D. Anderson Cancer Center
Tumor-Stromal Interactions in Breast Cancer Bone Metastasis
- Jeffrey Winkles, Ph.D.**
University of Maryland School of Medicine
TWEAK: A New Molecular Target for Breast Cancer Therapy?
- Junjie Chen, Ph.D.**
Mayo Clinic Rochester
Understanding the Tumor Suppression Function of BRCA1

Lily Wu, Ph.D., M.D.
University of California, Los Angeles
Use of Molecular Imaging and Genetic Approaches to Investigate the Role of Tumor Lymphangiogenesis in Breast Cancer Metastasis

Christopher Umbricht, M.D., Ph.D.
Johns Hopkins University
Value of molecular markers in predicting long-term outcome in ductal carcinoma in situ of the breast

Yong Liao, Ph.D.
University of Texas
M.D. Anderson Cancer Center
Wip1 As A Novel Therapeutic Target For Human Breast Cancer

CANCER CONTROL, SURVIVORSHIP AND OUTCOMES RESEARCH

Vanessa Sheppard, Ph.D.
Georgetown University
A Navigator Delivered Skills Intervention to Improve Communication and Decision-Making Among African American Breast Cancer Patients

Deborah Erwin, Ph.D.
University of Arkansas for Medical Sciences
A Study of Effectiveness of Esperanza y Vida: A Breast Cancer Intervention for Immigrant Latinas

Tsu-Yin Wu, Ph.D.
Eastern Michigan University
An Interdisciplinary Innovative Approach to Promote Breast Cancer Screening Among New Immigrant Women from Southeastern and Southern Asia

Kathy Helzlsouer, M.D.
Johns Hopkins University and
Mercy Medical Center
Being Well, Staying Healthy: An Integrated Mind-Body Medicine Intervention to Decrease Fatigue Among Breast Cancer Survivors

Elissa Ozanne, Ph.D.
Massachusetts General Hospital
Breast Cancer Prevention: Methods of Risk Communication

Tim Byers, M.D.
University of Colorado
Health Science Center
Cancer Rehabilitation for Low Income and Hispanic Breast Cancer Patients

Carolyn Rabin, Ph.D.
Miriam Hospital
Feasibility of Physical Activity and Relaxation Training for Cancer Survivors

Wayne Bardwell, Ph.D., M.B.A.
University of California, San Diego
Functioning, Fatigue & Psychological Distress in Breast Cancer Survivors: A 4-Yr Follow-Up Study

Amelie Ramirez, Dr.P.H.
Baylor College of Medicine
Genetic Evaluation for Breast Cancer Susceptibility In Hispanic and Non-Hispanic White Women In South Texas

Phyllis Butow, Ph.D.
University of Sydney
Improving Informed Consent: A Randomised Controlled Trial of a Decision Aid for Women Invited to Participate in a Breast Cancer Prevention Trial (IBIS-2)

Tracy Battaglia, M.D., M.P.H.
Boston University School of Medicine
Improving Mammography Follow-up at an Inner-City Community Health Center

Ka Kit Hui, M.D.
University of California, Los Angeles
Improving Outcomes: A Pilot Study of an Integrative East-West Medical Model for Survivors with Chronic Disabling Symptoms

Polly Newcomb, Ph.D., M.P.H.
University of Wisconsin
Comprehensive Cancer Center
Influence of Diet and Lifestyle on Breast Cancer Outcome

Ana Abraido-Lanza, Ph.D.
Columbia University
Latina Women and Breast Cancer Screening: Sociocultural Factors

Mary Kosir, M.D.
Wayne State University
Linking Lymphedema to Disorders of Lymphangiogenesis

Osman Galal, M.D., Ph.D.
University of California, Los Angeles
Muslim Women's Perceptions, Needs and Barriers to Breast Cancer and Screening

Amy Trentham-Dietz, Ph.D.
University of Wisconsin
Quality of Life Before and After a Breast Cancer Diagnosis in Older Women

Carolyn Gotay, Ph.D.
University of Hawaii
Quality of Life in Long-Term, Multiethnic Breast Cancer Survivors

Linda Burhansstipanov, Dr.P.H.
Native American Cancer Research
Quality of Life: Native American Cancer Education for Survivors (NACES)

Judy Huei-yu Wang, Ph.D.
Georgetown University
Reducing Disparities in Breast Cancer Screening in Chinese American Women

Maggie DeBon, Ph.D.
University of Tennessee
Health Science Center
Treatment of Hot Flashes in Breast Cancer Survivors: A Pilot Study

Kimberly Engelman, Ph.D.
University of Kansas Medical Center
Use Of Radiolucent Pad To Reduce Mammography Discomfort Among African Americans

Myungsun Yi, Doctor of Nursing Science
College of Nursing,
Seoul National University
Web-based Breast Cancer Educational Program in Korea

Berta Geller, Ed.D.
University of Vermont and
State Agricultural College
Why Some Breast Cancer Survivors Do Not Use Surveillance Mammography

Laura Porter, Ph.D.
Duke University
Yoga of Awareness Program for Menopausal Symptoms in Women at High Risk for Breast Cancer

EARLY DETECTION, DIAGNOSIS AND PROGNOSIS

Yuko Kono, M.D., Ph.D.
University of California, San Diego
A New MRI Dextran-Based Contrast Agent for Early Detection and Diagnosis of Breast Cancer

Jonathan Uhr, M.D.
University of Texas
Southwestern Medical Center at Dallas
A Novel Approach to Monitor Genetic Changes Associated with Breast Cancer Progression

John Boone, Ph.D.
University of California, Davis
Contrast-Enhanced Dual Energy Mammography

Joe Gray, Ph.D.
Ed Lawrence Berkeley National Laboratory
Development of Markers that Predict Resistance to Omnitarg in Breast Cancer

Hyunsuk Shim, Ph.D.
Emory University
F18-PET Detection of Breast Cancer Micrometastasis by CXCR4 Antagonist

Mei-yu Yu, Ph.D., M.D.
University of Michigan
*Factors Influencing Utilization of
Early Breast Cancer Detection in China*

Mary Ann Chiasson, Dr.P.H.
Medical & Health Research Association
of New York City
*Health Literacy as a Predictor of Complete
Breast Cancer Screening & Follow-Up*

Azra Alizad, M.D.
Mayo Clinic College of Medicine
*Identification and Differentiation of Breast
Masses by a Novel Imaging Method*

Jinong Li, Ph.D.
Johns Hopkins University
*Identification and Validation of Biomarkers for
Breast Cancer in Nipple Aspiration Fluid*

Jun Liu, Ph.D.
Ohio State University
*Imaging Breast Cancer Markers with
Nanoparticle Enhanced Ultrasound*

Debra Tonetti, Ph.D.
University of Illinois
*Mechanism of Protein Kinase C Alpha-
Mediated Tamoxifen-Resistant Breast Cancer*

Carolyn Bertozzi, Ph.D.
University of California, Berkeley
*Metabolic Imaging of Breast Cancer
Glycosylation*

Deborah Rhodes, M.D.
Mayo Clinic Rochester
*Molecular Breast Imaging: Evaluation of a
New Technique Using Scintimammography
as a Potential Screening Tool for Women at
Increased Risk of Breast Cancer*

Qi-Huang Zheng, Ph.D.
Indiana University
*New PET Reporter Probes for Imaging HSV-tk
Gene Expression in Breast Cancer*

Alla Reznik, Ph.D.
Sunnybrook and Women's College
Health Sciences Centre
*Positron Emission Mammography Camera with
Avalanche Gain*

Michael Tainsky, Ph.D.
Wayne State University
*Protein Microarrays for the Detection of
Breast Cancer*

Qing-Xiang Sang, Ph.D.
Florida State University
*Protein Signatures of Microinvasive (ER-) and
Adjacent Noninvasive (ER+) Cell Clusters
During the Progression of In Situ Lesions to
Invasive Carcinomas*

Melissa Clark, Ph.D.
Brown University
*Regular Mammography Screening:
The Realities for Women with Disabilities*

Ralf Landgraf, Ph.D.
University of California, Los Angeles
*Spiegelmers as Inhibitors and Targeting Vehicles
Against ErbB Receptors*

Shuang Liu, Ph.D.
Purdue University
*Tc-99m Labeled Multivalent RGD peptide for
Breast Cancer Imaging*

ETIOLOGY

James Ford, M.D.
Stanford University
*A Clinic-Based Study of BRCA Mutation
Carriage, Differences in BRCA1/2 Scores,
and Breast Cancer Risk Factors Among Asians
and Caucasians*

Christopher Haiman, Sc.D.
University of Southern California
*A Comprehensive Genomic Approach to
Characterize the Role of Genetic Variation in
IGF Receptor Genes in Relation to Breast
Cancer Risk: The Multiethnic Cohort*

Rosa Crum, M.D., M.H.S.
Johns Hopkins University
Bloomberg School of Public Health
*A Prospective Study of Alcohol Intake,
Genetic Susceptibility and Breast Cancer
Overall Health Risk*

Geoffrey Greene, Ph.D.
University of Chicago
*Estrogen Receptor AF-1 Interacting
Proteins and Peptides*

Gail Tomlinson, M.D., Ph.D.
University of Texas
Southwestern Medical Center at Dallas
*Ethnicity and Outcomes of Breast Cancer
Genetic Counseling, Testing and Follow-up
Risk Reduction Measures*

William Kerr, Ph.D.
H. Lee Moffitt Cancer Center
and Research Institute
*LRBA: A Target for More Effective Breast
Cancer Treatments*

Jeannette Korczak, Ph.D.
Wayne State University
*Molecular Epidemiology of Steroid Hormone
Metabolism in Relation to Breast Cancer Risk
in African Americans*

Wen Xie, M.D., Ph.D.
University of Pittsburgh
*Orphan Nuclear Receptor PXR in Estrogen
Deprivation and Breast Cancer*

PREVENTION

Reza Hakkak, Ph.D.
Arkansas Children's Hospital
Research Institute
*A New Animal Model for Breast Cancer
Development in Obese Post-Menopausal
Women: Mechanism and Role of Diet*

Virginia Borges, M.D.
University of Colorado
Health Science Center
*A Novel MUC1 Targeted Vaccine for the
Treatment of Breast Cancer*

Mickey Hu, Ph.D.
University of Texas
M.D. Anderson Cancer Center
*Activation of FOXO Tumor Suppressor for
Breast Cancer Therapy and Prevention*

Henry Lai, Ph.D.
University of Washington
*Artemisinin and Artemisinin-Tagged
Transferrin for Prevention and Treatment of
Breast Cancer*

Diane Lancaster, R.N., Ph.D.
Brigham and Women's Hospital
*Factors that Influence Breast Cancer Risk
Appraisal among Elderly African American and
Caucasian Women*

Thenaa Said, Ph.D.
Baylor College of Medicine
*INK4/ARF in Parity-Induced Protection of
Breast Cancer*

Judy Raucy, Ph.D.
California Toxicology Research Institute
*Mechanisms of Multi-Drug Resistance in Breast
Cancer Chemotherapy*

Ching-Shih Chen, Ph.D.
Ohio State University
*Sensitizing ER-Negative Breast Cancer Cells
to Tamoxifen-Induced Apoptosis by a Novel
PDK-1 Inhibitor*

Stanley Riddell, M.D.
Fred Hutchinson Cancer Research Center
*Targeting a Novel Breast Differentiation
Antigen for Breast Cancer Immunotherapy*

Robert Burack, M.D., M.P.H.
Wayne State University
*Utilizing Appointment Facilitation and
Reminder Systems to Increase Screening Among
Enrollees of the Wayne County BCCCP*

SCIENTIFIC MODEL SYSTEMS

Eric Greene, Ph.D.

Columbia University

Imaging the Molecular Mechanisms of DNA Damage Repair

Hallgeir Rui, Ph.D., M.D.

Georgetown University

Improved Xenotransplant Model for Human Breast Cancer

Debananda Pati, Ph.D.

Baylor College of Medicine

Role of Separase in Breast Cancer

TREATMENT

Lisa Kuhn, Ph.D.

University of Connecticut Health Center

A Lymph Node Targeted Anti-Cancer Drug Delivery System for Breast Cancer Metastases Based on Calcium Phosphate Particulates

Xianming Huang, Ph.D.

UT Southwestern Medical Center at Dallas

A Novel Vascular Targeting Antibody, 3G4, Enhances the Therapeutic Efficacy of Docetaxel Against Drug Resistant Breast Cancer and Metastases

Tara Breslin, M.D.

University of Wisconsin System

A Pilot Study of Intraoperative Margin Assessment Comparing Optical Spectroscopy and Frozen Section Analysis for Ductal Carcinoma In-Situ of the Breast

Ramon Colomer, M.D., Ph.D.

Intitut Catala d'Oncologia – Hospital

Universitari Dr. Josep Trueta Antitumoral Efficacy of Novel Inhibitors of the Fatty Acid Synthase

Charles Patrick, Jr., Ph.D.

University of Texas

M.D. Anderson Cancer Center
Assessment of Adipose Tissue Engineering to Restore the Postmastectomy Breast

M. Jules Mattes, Ph.D.

Center for Molecular Medicine and Immunology

Auger Electron Emitters for Breast Cancer Radioimmunotherapy

Robert Jeraj, Ph.D.

University of Wisconsin, Madison

Characterization of Breast Motion and its Dosimetric Consequences

Ana Tari, Ph.D.

University of Texas

M.D. Anderson Cancer Center
Cyclooxygenase-2 Protein and Tamoxifen Resistance in Breast Cancer

Nouri Neamati, Ph.D.

University of Southern California

Development of Selective AP-Site Directed Drugs in Breast Cancer

Michael Barry, Ph.D.

Baylor College of Medicine

Development of Breast Cancer Targeting Gene Therapy Vectors

Kelly Hunt, M.D.

University of Texas

M.D. Anderson Cancer Center
E2F-1 and Telomeres: A Combined Strategy for Treatment and Prognosis of Breast Cancer

Li-Xi Yang, M.D., Ph.D.

California Pacific Medical Center

Research Institute

Enhancement of Radiotherapy of Breast Cancer by a Novel Chemoradiosensitizing Agent

David Potter, M.D., Ph.D.

Indiana University

Epoxygenase Mechanisms of Breast Cancer Progression

Victor Krasnykh, Ph.D.

University of Texas

M.D. Anderson Cancer Center
Her2-Targeted Adenovirus Vectors for Imaging and Gene Therapy of Breast Cancer

Lei Xing, Ph.D.

Stanford University

Intensity Modulated Breast Irradiation Under the Guidance of PET/CT Imaging

Julia White, M.D.

Medical College of Wisconsin

Intensity Modulated Radiotherapy for Treatment of Breast Cancer Patients in Prone Position

Sara Rockwel, Ph.D.

Yale University

Interactions of Black Cohosh Extracts with Doxorubicin: Possible Mechanisms

Frank Marini, Ph.D.

University of Texas

M.D. Anderson Cancer Center
Mesenchymal Stem Cells as Cellular Delivery Vehicles for Control of Metastatic Breast Cancer

Antonio Wolff, M.D.

The Sidney Kimmel Cancer Center

at Johns Hopkins
Optimizing Oral Chemotherapy in Breast Cancer Using Fixed Dose Schedules: The Identification of Predictive Markers of Response and Toxicity to Capecitabine

Youssef Jounaidi, Ph.D.

Boston University

P450-armed Replication-Specific/Adaptive Adenovirus for Chemo-resistant Breast Cancer Treatment

Gabriela Chiosis, Ph.D.

Memorial Sloan-Kettering Cancer Center

Pre-Clinical Evaluation of Novel Hsp90 Inhibitors in Breast Cancer

Kaiyi Li, Ph.D.

Baylor College of Medicine

RNA Interference as a Novel Approach to Target Cyclin E Overexpression in Breast Cancer

Andrew Scott, M.B., B.S., F.R.A.C.P.

Ludwig Institute for Cancer Research

Targeted Immunotherapeutic Strategies in Breast Cancer

Marina Konopleva, M.D., Ph.D.

University of Texas

M.D. Anderson Cancer Center
Targeting PPARgamma by CDDO: A Novel Therapy for Resistant Breast Cancer

Noriyuki Kasahara, M.D., Ph.D.

University of California, Los Angeles

Targeting Retrovirus Replication for Gene Therapy of Breast Cancer

Kelly Hunt, M.D.

University of Texas

M.D. Anderson Cancer Center
Targeting the Cell Cycle in Breast Cancer Treatment

Jaime Merchan, M.D., M.M.Sc.

Mayo College of Medicine

The Plasminogen Activator System as a Target for Breast Cancer Virotherapy

Gary Molander, Ph.D.

University of Pennsylvania

Total Synthesis of Apoptolidin and Analogs

Mark Dewhirst, D.V.M., Ph.D.

Duke University

Using HIF-1 Blockade to Improve Chemotherapy Efficacy in Human Breast Cancer

Jian Qiao, M.D., Ph.D.


Mayo Clinic

VSV-G Pseudotyped, Semi-Replication-Competent Vector for Breast Cancer Gene Therapy

2004-2005 BOARD OF DIRECTORS

NORMAN BRINKER

Mr. Brinker is chairman emeritus of Brinker International, a restaurant group that includes Chili's Grill & Bar and Romano's Macaroni Grill, among others. Mr. Brinker began his career in the restaurant industry in 1957 with Jack-In-The-Box. He established Steak and Ale restaurants in 1965. Steak and Ale merged with Pillsbury in 1976, and in 1982, he became president of the Pillsbury Restaurant Group, overseeing such restaurants as Steak and Ale, Burger King and Bennigan's. In 1983, he invested in and became chairman and CEO of Chili's, Inc., now known as Brinker International. He has served on the Foundation Board since its inception in 1982.



LINDA CUSTARD

Ms. Custard is a full-time volunteer with a wide range of experience in educational, cultural and social service boards. She has served as president of the Junior League of Dallas, vice chair of the United Way of Metropolitan Dallas, chair of the Board of Trustees of the Hockaday School, president of the Community Council of Greater Dallas and president of the Dallas Woman's Club. Presently, she serves as a Trustee of Southern Methodist University and as a Director of the Dallas Center for the Performing Arts Foundation. She has served as a member of the Komen Foundation Board of Directors since 1991.

LASALLE D. LEFFALL, JR., M.D. – CHAIRMAN OF THE BOARD

Dr. Leffall is the Charles R. Drew Professor of Surgery at the Howard University College of Medicine. He is a surgeon, oncologist, medical educator and leader in professional and civic organizations. In May 2002, Dr. Leffall was appointed by President George W. Bush as a member and chair of the President's Cancer Panel. He graduated summa cum laude from Florida A&M University with a B.S. degree in 1948. He received his M.D. from Howard University College of Medicine, ranking first in his class. He was an intern at Homer G. Phillips Hospital, St. Louis, MO; assistant resident and chief resident in surgery at Freedmen's Hospital, Washington, D.C.; and senior fellow in cancer surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. Dr. Leffall began his military career at the rank of Captain, M.C., serving as Chief of General Surgery, U.S. Army Hospital, Munich, Germany, 1960-61. He joined the faculty at Howard University in 1962 as assistant professor. He continued with appointments as acting dean and professor. He became chairman of the department of surgery in 1970, a position he held for 25 years.



CONNIE O'NEILL

Ms. O'Neill has been involved with the Komen Foundation since 1992, serving as treasurer for two years previously and chairing the National Awards Luncheon in 1994. In 2000, she was again appointed treasurer of the Komen Foundation. Ms. O'Neill also serves on the boards of Children's Health Services of Texas, Children's Medical Center Foundation and Presbyterian Healthcare Foundation. She is a member of the Leadership Dallas Alumni Association and the Crystal Charity Ball. She was formerly president of the Junior League of Dallas and has also served on the boards of the United Way of Metropolitan Dallas, St. Paul Medical Center Foundation and the Southern Methodist University Alumni Association. Ms. O'Neill is a 1977 graduate of SMU and worked as a certified public accountant for Ernst & Young from 1977 to 1985.

KAREN RIVERA

As Affiliate Representative to the Komen Board of Directors, Ms. Rivera represented more than 100 Komen Affiliates across the country. A 15-year breast cancer survivor, she joined the Komen El Paso Affiliate in 1992. Since that time, she has held numerous leadership positions with the Affiliate, including president, Race chair, fundraising chair, survivor luncheon chair and executive committee member. Her additional volunteer work includes Las Palmas Medical Center Woman's Advisory Board, the Rotary Club of El Paso, the Advisory Board for Amigo Airsho and the Junior League of El Paso. Professionally, Ms. Rivera is a partner in Business Interiors, a commercial interior design firm.




LYNN SELLERS

Ms. Sellers is a past Komen Race for the Cure® chair and long-time volunteer with the Komen Charleston Affiliate. She was instrumental in forming the Komen Charleston Affiliate's board in 1999, served as the survivor luncheon chair in 2000-2001 and was honored as the local hero for the BMW Ultimate Drive in 2001. She currently serves as a member of the Foundation's Volunteer Advisory Council. Ms. Sellers earned a B.S. in Economics from the College of Charleston.

ROBERT TAYLOR

Mr. Taylor is general counsel at Taylor Lohmeyer Corrigan, P.C. He also serves as chairman of the Dallas/Fort Worth Duke University Alumni Admissions Committee and is past chairman of the Highland Park United Methodist Church Board of Trustees. Mr. Taylor received his A.B. and J.D. from Duke University and received his L.L.M. and S.J.D. in Taxation from Georgetown Law Center. He has served as a member of the Komen Foundation Board of Directors since 1991.



MELISSA WAGGENER-ZORKIN

Ms. Waggener-Zorkin founded the public relations firm Waggener Edstrom in 1983 and currently serves as president and CEO of the now worldwide agency. She also serves on the board of directors for the Technology Alliance and has been a longtime supporter of the Fred Hutchison Cancer Research Center and the Komen Oregon and Southwest Washington Affiliate.

BARNEY YOUNG

Mr. Young is general counsel at Locke Liddell & Sapp LLP and has served on the Komen Board since 2000. Mr. Young also serves on the Board of Trustees for Friends of the Center for Human Nutrition, the Shelter Ministries of Dallas Foundation, the Dallas Historical Society and the National Association of Independent Schools. A magna cum laude graduate of Yale University, Mr. Young received his J.D. with honors from the University of Texas Law School.



NANCY GOODMAN BRINKER

FOUNDER, THE SUSAN G. KOMEN BREAST CANCER FOUNDATION



When Nancy Brinker's sister, Suzy, died of breast cancer at the age of 36 in 1980, Nancy promised herself that she would fulfill her sister's plea to help others battling the disease. In 1982, she established the Susan G. Komen Breast Cancer Foundation, today recognized as a global leader in the fight against breast cancer through its support of innovative research and community-based outreach programs. Currently, the Komen Foundation boasts more than 75,000 volunteers working in 15,000 communities. Ms. Brinker also founded the Komen Foundation's signature program – the Komen Race for the Cure®, the largest series of 5K runs/fitness walks in the world. Since its origin in 1983 in Dallas, the Komen Race for the Cure® Series has grown from one local Race with 800 participants to a national series of more than 100 Races with more than 1 million annual participants.

In 2001, President Bush appointed Ms. Brinker to serve as U.S. Ambassador to the Republic of Hungary. In 1986, President Reagan appointed Ms. Brinker to the 18-member National Cancer Advisory Board as one of six laypeople. In 1992, she was appointed by President Bush to the three-member President's Cancer Panel to monitor the progress of the National Cancer Program and was appointed by Vice President Quayle to serve as the Chairperson of a subcommittee to study the progress of breast cancer research and education in the United States and around the world. In recognition of her lifetime of work in the breast cancer field, Ms. Brinker received the 2005 Mary Woodard Lasker Award for Public Service presented by the Albert and Mary Lasker Foundation.

Prior to assuming her position as Ambassador, she served on the boards of Manpower, Inc., United Rentals, Inc., and U.S. Oncology. In addition, Ms. Brinker served on the national advisory boards of the Harvard Center for Cancer Prevention, Women's Health Resource Center, Women's Health Initiative, the National Coalition of Cancer Survivorship and the National Cancer Institute. She is a former board member of such not-for-profit organizations as the National Jewish Coalition Board of Governors, New York University's Medical School Foundation, and National Surgical Adjuvant Breast Project. Ms. Brinker has testified before the United States Democratic Policy Committee's Congressional Breast Cancer Forum and participated in the International Women's Forum.

2004-2005 STAFF LEADERSHIP



Susan Braun
*President and Chief Executive Officer**



Rebecca Garcia, Ph.D.
Vice President, Health Sciences



Patrice Tosi
Chief Operating Officer, Executive Vice President



Andrew Halpern
Vice President, General Counsel



Nancy Byrd
Vice President, Domestic Affiliate Network



Cindy Schneible
Vice President, Cause Related Marketing

** After nine years of dedicated service, Ms. Braun left the Komen Foundation in August 2005 to pursue new opportunities. We applaud her work and commitment to the fight against breast cancer.*

